Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 405 • 2016 ACR/ARHP Annual Meeting
Patterns of Medication Use in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Sarah Ringold¹, Yukiko Kimura², Laura E. Schanberg³, Marc D. Natter⁴, Fenglong Xie⁵, Norman Ilowite⁶, Jason Jones⁷, Kelly Mieszkalski⁸, Timothy Beukelman⁹ and for the CARRA Registry Investigators, ¹Pediatrics, Seattle Children's Hospital, Seattle, WA, ²Hackensack University Medical Center, Hackensack, NJ, ³Pediatrics, Duke Medical Center, Durham, NC, ⁴Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁷Childhood Arthritis and Research Rheumatology Alliance (CARRA), Durham, NC, ⁸Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, ⁹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multicenter, prospective observational study collecting data from children with rheumatic diseases in order…
Abstract Number: 2417 • 2016 ACR/ARHP Annual Meeting
High Dimensional Interrogation of the T Cell Immunome in Polyarticular Juvenile Idiopathic Arthritis Patients
Jing Yao Leong¹, Justin Tiong², Joo Guan Yeo^2,3, Liyun Lai¹, Phyllis Chen³, Loshinidevi D/O Thana Bathi³, Thaschawee Arkachaisri², Daniel J Lovell⁴ and Salvatore Albani^1,5, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Singhealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ⁴PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁵Duke-National University of Singapore Medical School, Singapore, Singapore
Background/Purpose: Clinical management of polyarticular JIA with anti-TNF-alpha has been met with moderate success, with up to 50% of patients demonstrating clinically meaningful efficacy. Concerns…
Abstract Number: 406 • 2016 ACR/ARHP Annual Meeting
Adults with Juvenile Idiopathic Arthritis Are Not Adults with Rheumatoid Arthritis
Rayford R. June¹, Danielle Feger², Nicholas Longson³, Barbara E. Ostrov^4,5 and Nancy J. Olsen⁶, ¹Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ²Medicine/Rheumatology, Penn State College of Medicine, Hershey, PA, ³Johns Hopkins University, Baltimore, MD, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, ⁶Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) persisting into adulthood is associated with articular damage, increased disability and mortality. Approximately 100,000 polyarticular JIA patients will enter adult…
Abstract Number: 3114 • 2016 ACR/ARHP Annual Meeting
Cardiorespiratory Fitness in Children with Juvenile Idiopathic Arthritis Treated in the Biological Era Is Comparable with Controls- a Cross-Sectional Study
Kristine Risum¹, Elisabeth Edvardsen^2,3, Anne Marit Selvaag⁴, Oyvind Molberg⁴, Hanne Dagfinrud⁵ and Helga Sanner^4,6, ¹Department of Rehabilitation, Division of Orthopeadic Surgery, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Sports Medicine, Norwegian School of Sport Sciences, Oslo, Norway, Oslo, Norway, ³Department of Pulmonary Medicine, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Cardiorespiratory Fitness in Children with Juvenile Idiopathic Arthritis Treated in the Biological Era is Comparable with Controls- a Cross-Sectional Study Background/Purpose: Reduced cardiorespiratory fitness (CRF)…
Abstract Number: 407 • 2016 ACR/ARHP Annual Meeting
Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA
Stephanie J.W.Shoop^1,2, Kimme L. Hyrich^3,4, Suzanne M.M. Verstappen⁴, Wendy Thomson^5,6, Janet E. McDonagh⁷ and CAPS, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom
Background/Purpose: It is unclear which tool should measure functional ability in adolescents with JIA. The proxy-completed Childhood Health Assessment Questionnaire (P-CHAQ) is completed on the…
Abstract Number: 3115 • 2016 ACR/ARHP Annual Meeting
Reconsidering the Juvenile Idiopathic Arthritis Core Set: How Patients and Caregivers Define Disease Activity
Jennifer R. Horonjeff¹, Susan Thornhill², Daniel B. Horton³, Jennifer N. Stinson⁴, Anjali Fortna⁵, Stephanie Luca⁶, Arlene Vinci⁷, Laura C. Marrow⁸, Emily L. Creek⁷, Meredith Riebschleger⁹, Alessandro Consolaro¹⁰, Jane Munro¹¹, Vibeke Strand¹², Clifton Bingham III¹³ and Esi Morgan¹⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Thornhill Associates, Hermosa Beach, CA, ³Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁴Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Columbia University Medical Center, New York, NY, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Consumer Health, Arthritis Foundation, Atlanta, GA, ⁸Arthritis Foundation, Atlanta, GA, ⁹Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ¹⁰Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ¹¹Rheumatology, Royal Children's Hospital, Parkville, Australia, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³Divisions of Rheumatology and Allergy, Department of Medicine, Johns Hopkins University, Johns Hopkins University, Baltimore, MD, ¹⁴Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: The current JIA Core Set (ACR Pediatric 30) contains items that should be assessed in clinical trials for children with JIA. It was developed…
Abstract Number: 958 • 2015 ACR/ARHP Annual Meeting
The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Jens Klotsche¹, Gerd Ganser², Ivan Foeldvari³, Hans Huppertz⁴, Rolf M. Kuester⁵, Angelika Thon⁶, Kirsten Minden⁷ and Gerd Horneff⁸, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁴Prof Hess Children’s Hospital, Bremen, Germany, ⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ⁶Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, ⁷Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁸Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany
Background/Purpose: Methotrexate (MTX) is the most widely used disease modifying antirheumatic drug (DMARD) in JIA and regarded to be a safe drug, effective in around…
Abstract Number: 2446 • 2015 ACR/ARHP Annual Meeting
Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course
AnneMarie C. Brescia¹, Megan M. Simonds², Kathleen E. Sullivan³ and Carlos D. Rose⁴, ¹Pediatric Rheumatology, Nemours A.I. duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE, ³Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Children with oligoarticular juvenile idiopathic arthritis (JIA) who have an extended course (recruitment of 5 or more joints after 6 months of disease) have…
Abstract Number: 1293 • 2015 ACR/ARHP Annual Meeting
A Comparison of Prenatal Care in Mothers with and without JIA: Association with Outcomes
Debbie Ehrmann Feldman¹, Anick Bérard², Evelyne Vinet³, Ciarán M. Duffy⁴, Elizabeth Hazel⁵, Marie-Pierre Sylvestre⁶, Garbis Meshefedjian⁷ and Sasha Bernatsky⁸, ¹School of Rehabilitation, Université de Montréal, Montreal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁵Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁶Université de Montréal, Montreal, QC, Canada, ⁷Public Health Department of Montreal, Montreal, QC, Canada, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada
Background/Purpose: Women who had JIA in childhood and adolescence may be at higher risk for adverse neonatal and maternal outcomes. Our objective was to examine…
Abstract Number: 3147 • 2015 ACR/ARHP Annual Meeting
Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease
Janalee Taylor¹, Edward H. Giannini¹, Daniel Lovell² and Esi M. Morgan DeWitt¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: With the advent and implementation of advanced drug therapy clinical inactive disease (CID) has become an attainable target in the treatment of juvenile idiopathic…
Abstract Number: 1463 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis
Hannah Peckham¹, Lauren Bourke^2,3, Anna Radziszewska⁴, Maria Leandro⁵, Debajit Sen², Geraldine Cambridge⁶ and Yiannis Ioannou^7,8, ¹Adolescent Centre for Rheumatology Research, University College London, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴The Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁸Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose: Raised levels of Rheumatoid Factor (RhF) and antibodies to citrullinated proteins (ACPA), detected in the clinic using combinations of cyclic citrullinated peptides (CCP), are…
Abstract Number: 3150 • 2015 ACR/ARHP Annual Meeting
Virtual Peer-to-Peer Mentoring Support for Adolescents with Juvenile Idiopathic Arthritis: The Virtual Peer-to-Peer Program
Jennifer N. Stinson¹, Sara Ahola Kohut^2,3, Khush Amaria², Mary J. Bell⁴, Paula Forgeron⁵, Miriam Kaufman⁶, Nadia Luca⁷ and Lynn R. Spiegel⁸, ¹Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheum Div/Univ of Toronto, University of Toronto, Toronto, ON, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶Adolescent Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁸Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic disease that results in physical and emotional symptoms as well as difficulties in social and role…
Abstract Number: 1468 • 2015 ACR/ARHP Annual Meeting
The Proposed Outcome Parameters of the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) with Uveitis Disability VAS Score Correspond Significantly with Uveitis “Classicaly Assessed” Uveitis Activity
Ivan Foeldvari¹, Sandra Schenck², Gabriele Simonini³, Cinzia DeLibero⁴, Gabriele Brumm⁵, Kaisu Kotaniemi⁶, Susan Mary Nielsen⁷, Regitze Bangsgaard⁷, Irene Pontikaki⁸, Valeria Maria Gerloni⁸, Elisabetta Miserocchi⁹, Vasco Miranda¹⁰, Margarida Guedes¹¹, Sheila T. Angeles-Han¹², Steven Yeh¹³, Jordi Anton¹⁴, Rosa Bou Torrent¹⁵, Carmen García de Vicuña¹⁶, Martina Niewerth¹⁷ and Arnd Heiligenhaus¹⁸, ¹Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ²Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ³Pediatric Rheumatology, Pediatric Rheumatology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy, ⁴Ophthalmology Unit, Anna Meyer Children's Hospital, Florence, Italy, ⁵Klinik und Polyklinikum für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, ⁶Ophthalmology Department, Rheumatism Foundation Hospital, Heinola, Finland, ⁷Rigshospitalet, Copenhagen, Denmark, ⁸Dipartimento di Reumatologia, Università di Milano - Istituto Gaetano Pini, Milano, Italy, ⁹Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, ¹⁰Centro Hospitalar do Porto, Porto, Portugal, ¹¹Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal, ¹²Pediatrics, Emory Children's Center, Atlanta, GA, ¹³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ¹⁴Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ¹⁵Pediatrics Department, Pediatric Rheumatology Unit, Universitat de Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain, ¹⁶Universitat de Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain, ¹⁷Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹⁸Department of Ophthalmology at St. Franziskus Hospital Muenster, University of Duisberg-Essen, Muenster, Germany
Background/Purpose: Juvenile idiopathic arthritis (JIA) associated uveitis is one of the most severe comorbidities of JIA and occurs in around 10% of JIA patients. There…
Abstract Number: 3178 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 13 Cases
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Inmaculada Calvo², Marina Mesquida³, Alfredo Adan³, M. Victoria Hernández⁴, Olga Maiz Alonso⁵, Antonio Atanes-Sandoval⁶, Beatriz Bravo⁷, Consuelo Modesto⁸, Gisela Diaz Soriano⁹, Javier Loricera¹, Leyre Riancho-Zarrabeitia¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital La Fe, Valencia, Spain, ³Ophthalmology, Hospital Clinic, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Rheumatology, Donostia University Hospital, Donostia, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ⁷Rheumatology, Hospital Universitario HUVN, Granada, Spain, ⁸Rheumatology, Hospital HSLL, Palma de Mallorca, Spain, ⁹Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to juvenile idiopathic arthritis (JiA).Methods: Multicenter study of uveitis related to JiA…
Abstract Number: 1470 • 2015 ACR/ARHP Annual Meeting
A Population-Based Study of Outcomes of Patients with Juvenile Idiopathic Arthritis (JIA) Compared to Non-JIA Subjects
Megan L. Krause¹, J.A. Zamora-Legoff², Cynthia S. Crowson³, Thomas Mason II¹, Theresa Wampler Muskardin² and Eric L. Matteson⁴, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The impact of juvenile idiopathic arthritis (JIA) is not confined to joint involvement in children but rather widespread effects extending to adulthood. This study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].